To identify patients at risk of progression to B cell malignancies from early precursor conditions such as Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) and develop targeted therapies to eliminate the disease before it progresses.
To identify mechanisms of progression in Multiple Myeloma. We examine the genetic, epigenetic, and immune alterations that regulate tumor dissemination and the role of the bone marrow niche in disease progression.
Current projects include:
Identifying factors that regulate disease progression in patients with MGUS/SMM to overt MM.
Understanding progression risk and identifying patients with precursor disease who would benefit most from early intervention.
Identifying novel immunotherapy targets and strategies in MM and MUGS/SMM.
Mechanisms of early cell dissemination and clonal heterogeneity.
The use of circulating tumor cells and cell-free DNA as disease biomarkers.
Defining the role of the bone marrow niche in regulating clonal evolution and disease progression.
Identifying novel biomarkers of disease progression in precursor hematological malignancies.
Examining the cell-cell interactions of plasma cells in MM.
Therapeutic targeting of the bone marrow niche and interception of disease progression in myeloma.
Examining novel targets in clinical trials in Multiple Myeloma and Waldenstrom Macroglobulinemia (WM).
The role of the bone marrow niche in regulating drug resistance in MM.